OverviewSuggest Edit

MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
TypePublic
Founded2012
HQSouth San Francisco, US
Websitemyokardia.com
Employee Ratings4.4

Latest Updates

Employees (est.) (Dec 2019)235(+43%)
Job Openings29
Revenue (FY, 2019)$0(-100%)
Share Price (May 2020)$107.5

Key People/Management at MyoKardia

Tassos Gianakakos

Tassos Gianakakos

CEO, Director
William Fairey

William Fairey

Executive Vice President, Chief Commercial Officer
Robert S. McDowell

Robert S. McDowell

Chief Scientific Officer
Jake Bauer

Jake Bauer

Chief Business Officer
Taylor Harris

Taylor Harris

CFO
Ingrid Boyes

Ingrid Boyes

Senior Vice President, Human Resources
Show more

MyoKardia Office Locations

MyoKardia has an office in South San Francisco
South San Francisco, US (HQ)
333 Allerton Ave
Show all (1)

MyoKardia Financials and Metrics

MyoKardia Revenue

USD

Net income (Q1, 2020)

(69.9m)

EBIT (Q1, 2020)

(71.8m)

Market capitalization (22-May-2020)

5.7b

Closing stock price (22-May-2020)

107.5

Cash (31-Mar-2020)

131.2m

EV

5.6b
MyoKardia's current market capitalization is $5.7 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

39.2m22.5m33.6m

Revenue growth, %

176%(43%)49%

General and administrative expense

16.3m22.0m38.4m61.7m

R&D expense

36.2m48.1m68.8m146.2m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

5.6m5.6m5.6m5.3m6.6m9.2m

General and administrative expense

5.5m5.1m5.9m7.3m8.9m11.0m13.6m13.9m17.7m19.9m

R&D expense

11.9m13.7m14.4m16.6m17.2m15.9m26.2m27.7m47.4m51.9m

Operating expense total

17.4m18.8m20.2m23.9m26.1m26.9m39.7m41.6m145.1m71.8m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

135.8m224.6m246.1m101.4m

Prepaid Expenses

1.4m1.9m4.8m7.7m

Current Assets

186.3m259.4m319.4m423.8m

PP&E

2.8m3.1m5.1m15.7m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(13.2m)(46.0m)(67.7m)(276.2m)

Depreciation and Amortization

1.1m1.3m1.6m1.9m

Accounts Payable

(434.0k)367.0k671.0k3.1m

Cash From Operating Activities

(20.9m)(9.8m)(64.8m)(241.8m)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(11.5m)(24.4m)(38.6m)(17.8m)(36.2m)(52.0m)(37.5m)(75.6m)(217.4m)(69.9m)

Depreciation and Amortization

316.0k634.0k977.0k300.0k723.0k1.1m461.0k944.0k1.4m

Accounts Payable

629.0k(488.0k)228.0k212.0k698.0k357.0k2.0m281.0k3.6m(467.0k)

Cash From Operating Activities

28.0m13.8m(3.2m)(16.6m)(32.2m)(47.0m)(38.0m)(65.1m)(188.9m)(59.9m)
USDY, 2020

EV/EBIT

-77.9 x

EV/CFO

-93.3 x

Financial Leverage

1.3 x
Show all financial metrics

MyoKardia Operating Metrics

FY, 2015FY, 2016FY, 2017FY, 2018

Phase II Trials Products

1 1 2

Phase I Trials Products

2 2 2 1

Preclinical Phase Products

1 3 3

Patents (US)

2 3 4 2
Show all operating metrics

MyoKardia Acquisitions / Subsidiaries

Company NameDateDeal Size
MyoKardia Australia Pty Ltd

MyoKardia Online and Social Media Presence

Embed Graph

MyoKardia Company Culture

  • CEO Rating

    A+

    90/100

  • Compensation

    A+

    100/100

Learn more on Comparably

MyoKardia News and Updates

MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy Patients

MAVERICK-HCM Phase 2 Clinical Trial Results Consistent with Tolerability Observations from Prior Studies of Mavacamten

MyoKardia Provides Clinical Trial Update in the Context of the COVID-19 Pandemic

Reaffirms Second Quarter 2020 Expected Timing for Topline Data from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten and Phase 2a Danicamtiv Study Reaffirms Second Quarter 2020 Expected Timing for Topline Data from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten and Phase 2a Danicamtiv Study

MyoKardia Announces 48-week Data from PIONEER-OLE Study of Mavacamten

Mavacamten’s Safety and Efficacy Profile in the PIONEER Study Maintained Through One Year in Open-Label Extension Study of 12 Patients with Symptomatic, Obstructive HCM

MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten

Achieved Primary Study Objective of Safety and Tolerability in Patients with Non-obstructive HCM

MyoKardia Reports Third Quarter 2019 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the quarter ended September 30, 2019.

MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients

Planned Study Will Assess Effect of Mavacamten on the Need for SRT Among HCM Patients Referred for Invasive Procedures Planned Study Will Assess Effect of Mavacamten on the Need for SRT Among HCM Patients Referred for Invasive Procedures
Show more

MyoKardia Frequently Asked Questions

  • When was MyoKardia founded?

    MyoKardia was founded in 2012.

  • Who are MyoKardia key executives?

    MyoKardia's key executives are Tassos Gianakakos, William Fairey and Robert S. McDowell.

  • How many employees does MyoKardia have?

    MyoKardia has 235 employees.

  • Who are MyoKardia competitors?

    Competitors of MyoKardia include Achaogen, AbbVie and Abbott.

  • Where is MyoKardia headquarters?

    MyoKardia headquarters is located at 333 Allerton Ave, South San Francisco.

  • Where are MyoKardia offices?

    MyoKardia has an office in South San Francisco.

  • How many offices does MyoKardia have?

    MyoKardia has 1 office.